

CORRECTION

Open Access



Correction: PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients

Daniele Giardiello^{1,2,3}, Maartje J. Hooning⁴, Michael Hauptmann⁵, Renske Keeman¹, B. A. M. Heemskerk-Gerritsen⁴, Heiko Becher⁶, Carl Blomqvist^{7,8}, Stig E. Bojesen^{9,10,11}, Manjeet K. Bolla¹², Nicola J. Camp¹³, Kamila Czene¹⁴, Peter Devilee^{15,16}, Diana M. Eccles¹⁷, Peter A. Fasching^{18,19}, Jonine D. Figueroa^{20,21,22}, Henrik Flyger²³, Montserrat García-Closas²², Christopher A. Haiman²⁴, Ute Hamann²⁵, John L. Hopper²⁶, Anna Jakubowska^{27,28}, Floor E. Leeuwen²⁹, Annika Lindblom^{30,31}, Jan Lubiński²⁷, Sara Margolin^{32,33}, Maria Elena Martinez^{34,35}, Heli Nevanlinna³⁶, Ines Nevelsteen³⁷, Saskia Pelders⁴, Paul D. P. Pharoah^{12,38}, Sabine Siesling^{39,40}, Melissa C. Southey^{41,42,43}, Annemieke H. van der Hout⁴⁴, Liselotte P. van Hest⁴⁵, Jenny Chang-Claude^{46,47}, Per Hall^{14,32}, Douglas F. Easton^{12,38}, Ewout W. Steyerberg^{2,48} and Marjanka K. Schmidt^{1,29*}

Correction to: Breast Cancer Research (2022) 24:69

<https://doi.org/10.1186/s13058-022-01567-3>

Following publication of the original article [1], the authors flagged the following error in the '3. Formula to estimate the contralateral breast cancer risk using PredictCBC-2.0A' section of additional file 1: '+ 0.065 × I[Radiotherapy to the breast = yes]' had been written in place of '- 0.065 × I[Radiotherapy to the breast = yes]'.

The file has since been corrected. The authors thank you for reading and apologize for any inconvenience caused.

Author details

¹Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni Van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. ²Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands. ³Institute of Biomedicine, EURAC Research Affiliated Institute of the University of Lübeck, Bolzano, Italy. ⁴Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. ⁵Brandenburg Medical School, Institute of Biostatistics and Registry Research, Neuruppin, Germany. ⁶Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. ⁷Department of Oncology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland. ⁸Department of Oncology, Örebro University Hospital, Örebro, Sweden. ⁹Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark. ¹⁰Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark. ¹¹Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. ¹²Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK. ¹³Department of Internal Medicine and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. ¹⁴Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. ¹⁵Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands. ¹⁶Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands. ¹⁷Faculty of Medicine, University of Southampton, Southampton, UK. ¹⁸Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA. ¹⁹Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg (FAU), Erlangen, Germany. ²⁰Usher Institute of Population Health

The original article can be found online at <https://doi.org/10.1186/s13058-022-01567-3>.

*Correspondence: mk.schmidt@nki.nl

¹ Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni Van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Sciences and Informatics, The University of Edinburgh, Edinburgh, UK. ²¹Cancer Research UK Edinburgh Centre, The University of Edinburgh, Edinburgh, UK. ²²Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. ²³Department of Breast Surgery, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark. ²⁴Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. ²⁵Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany. ²⁶Melbourne School of Population and Global Health, Centre for Epidemiology and Biostatistics, The University of Melbourne, Melbourne, VIC, Australia. ²⁷Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland. ²⁸Independent Laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian Medical University, Szczecin, Poland. ²⁹Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute - Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands. ³⁰Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. ³¹Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden. ³²Department of Oncology, Södersjukhuset, Stockholm, Sweden. ³³Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden. ³⁴Moores Cancer Center, University of California San Diego, La Jolla, CA, USA. ³⁵Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA, USA. ³⁶Department of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland. ³⁷Department of Oncology, Leuven Multidisciplinary Breast Center, Leuven Cancer Institute, University Hospitals Leuven, Louven, Belgium. ³⁸Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK. ³⁹Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands. ⁴⁰Department of HealthTechnology and Services Research, Technical Medical Centre, University of Twente, Enschede, The Netherlands. ⁴¹Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia. ⁴²Department of Clinical Pathology, The University of Melbourne, Melbourne, VIC, Australia. ⁴³Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia. ⁴⁴Department of Genetics, University Medical Center Groningen, University Groningen, Groningen, The Netherlands. ⁴⁵Clinical Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. ⁴⁶Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. ⁴⁷Cancer Epidemiology Group, University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany. ⁴⁸Department of Public Health, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Published online: 22 November 2022

Reference

1. Giardiello, et al. PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients. *Breast Cancer Res.* 2022;24:69. <https://doi.org/10.1186/s13058-022-01567-3>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

